Summary of clinical trials with zafirlukast

被引：32

作者：

Calhoun, WJ ^{[1
]}

机构：

[1] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15261 USA

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 1998年 / 157卷 / 06期

关键词：

D O I：

10.1164/ajrccm.157.6.mar6

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Zafirlukast is an orally active and selective cysteinyl leukotriene (cysLT) receptor antagonist. In humans, zafirlukast antagonized the effects of exogenously administered LTD4 and cysLTs released endogenously in response to physical and chemical stimuli. Zafirlukast antagonized LTD4-induced bronchoconstriction, with effects still evident 12 h after drug administration. In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma, In multicenter trials in patients with chronic, stable asthma, zafirlukast reduced asthma symptoms, decreased as-needed beta-agonist use, and improved pulmonary function without increasing the number of adverse events, Zafirlukast also exhibited evidence of an anti-inflammatory effect in the lung in preliminary studies involving segmental antigen challenge. The results from these clinical trials demonstrate that zafirlukast is effective and safe for the prophylactic treatment of asthma.

引用

页码：S238 / S246

页数：9

共 31 条

[11]

Israel E., 1996, European Respiratory Journal Supplement, V9, p51S

[12] INHIBITION OF PLATELET-ACTIVATING FACTOR-INDUCED BRONCHOCONSTRICTION BY THE LEUKOTRIENE-D4 RECEPTOR ANTAGONIST ICI 204,219 [J].

KIDNEY, JC ;

RIDGE, SM ;

CHUNG, KF ;

BARNES, PJ .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (01) :215-217

[13] THE PROTECTIVE EFFECT OF INHALED LEUKOTRIENE-D(4) RECEPTOR ANTAGONIST ICI-204,219 AGAINST EXERCISE-INDUCED ASTHMA [J].

MAKKER, HK ;

LAU, LC ;

THOMSON, HW ;

BINKS, SM ;

HOLGATE, ST .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (06) :1413-1418

[14]

NATHAN RA, 1995, J ALLERGY CLIN IMMUN, V95, P388

[15] INHALED ICI-204,219 BLOCKS ANTIGEN-INDUCED BRONCHOCONSTRICTION IN SUBJECTS WITH BRONCHIAL-ASTHMA [J].

NATHAN, RA ;

GLASS, M ;

MINKWITZ, MC .

CHEST, 1994, 105 (02) :483-488

[16]

National Heart Lung and Blood Institute, 1995, NIH PUBL

[17]

*NIH NAT HEART LUN, 1997, HIGHL EXP PAN REP 2

[18] POTENT LEUKOTRIENE-D(4) RECEPTOR ANTAGONIST ICI-204,219 GIVEN BY THE INHALED ROUTE INHIBITS THE EARLY BUT NOT THE LATE-PHASE OF ALLERGEN-INDUCED BRONCHOCONSTRICTION [J].

OSHAUGHNESSY, KM ;

TAYLOR, IK ;

OCONNOR, B ;

OCONNELL, F ;

THOMSON, H ;

DOLLERY, CT .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (06) :1431-1435

[19] INHIBITION OF LEUKOTRIENE-D4-INDUCED BRONCHOCONSTRICTION IN NORMAL SUBJECTS BY THE ORAL LTD4 RECEPTOR ANTAGONIST ICI-204,219 [J].

SMITH, LJ ;

GELLER, S ;

EBRIGHT, L ;

GLASS, M ;

THYRUM, PT .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (04) :988-992

[20] INHIBITION OF LEUKOTRIENE D(4)-INDUCED BRONCHOCONSTRICTION IN SUBJECTS WITH ASTHMA - A CONCENTRATION-EFFECT STUDY OF ICI-204,219 [J].

SMITH, LJ ;

GLASS, M ;

MINKWITZ, MC .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (04) :430-436

← 1 2 3 4 →